Table 1.
Age | 56 (51, 63)a |
Gender | |
Male | 74 (70.5) |
Ethnicity | |
White | 88 (83.8) |
Education | |
Less than a bachelor's degree (< 15 years of education) | 78 (74.2) |
Profession | |
Employed | 50 (47.6) |
Sexual preference | |
Heterosexual | 62 (59) |
Homosexual | 25 (23.8) |
Source of HIV transmission | |
Heterosexual | 45 (42.9) |
Men who have sex with men | 41 (39) |
Number of co‐treatments | |
One | 19 (18) |
Two | 27 (25) |
More than two | 59 (56) |
Therapeutic classes of co‐treatment | |
Cardiovascular drugs | 79 (75.2) |
Antidepressants | 44 (42) |
Anxiolytics | 31 (29.5) |
Anti‐osteoporosis drugs | 29 (27.6) |
Oral antidiabetic drugs | 16 (15.2) |
HIV laboratory and clinical data | |
Undetectable HIV RNA (< 50 copies/mL) | 102 (97) |
CD4 count nadir (cells/μL) | 137 (64, 257)a |
CD4 count (cells/μL) | 707 (502, 918)a |
Time since HIV diagnosis (years) | 16.51 (11.6, 24.7)a |
Alcohol consumption | |
≤ 1 time monthly | 52 (49.5) |
2−4 times monthly | 18 (17.1) |
2−3 times weekly | 18 (17.1) |
Missing data | 17 (16.1) |
Injecting drug user | 3 (2.8) |
Adherence (self‐reported) | |
Adherent to cART | 87 (82.9) |
Adherent to co‐treatments | 75 (71.4) |
Self‐reported co‐treatments patients would be most likely to forget or not take (if any)b | |
Cardiovascular drugs | 14 (13.3) |
Antidepressants and anxiolytics | 8 (7.6) |
Anti‐osteoporosis drugs | 4 (3.8) |
Oral antidiabetic drugs | 1 (0.95) |
Morning doses of co‐treatments | 12 (11.4) |
Noon‐time doses of co‐treatments | 5 (4.8) |
Evening doses of co‐treatments | 17 (16.2) |
All co‐treatments | 3 (2.9) |
Total | 105 |
cART, combination antiretroviral therapy.
Values are expressed as n (%) unless otherwise indicated.
Expressed as median (Q1, Q3).
Patients had the options to select multiple answers and to write the name of the co‐treatment(s).